Increasing Prevalence of Autoimmune Diseases to Augment the Remicade Biosimilars Market Growth

 

Biosimilars Market Growth

Biosimilar is a bio-therapeutic drug that is similar in terms of safety, quality, and efficacy to an existing therapeutic drug. Biosimilars are a class of therapeutic drugs that provide additional treatment options and help reduce healthcare costs. They are almost identical to an existing therapeutic drugs and can only be manufactured when the patent for the original innovator drug expires.

Remicade biosimilars are used for the treatment of various autoimmune diseases such as ankylosing spondylitis, psoriatic arthritis, chronic severe plaque psoriasis, ulcerative colitis, Crohn's Disease, rheumatoid arthritis, etc. The number of biosimilars currently approved by the FDA is twenty-eight.

Market Dynamics

Increasing demand for biosimilar drugs and increasing incidence/prevalence of autoimmune diseases such as rheumatoid arthritis and plaque psoriasis is expected to propel the remicade biosimilar market growth. For instance, more than 24 people in the United States (more than 7% of the population) suffer from an autoimmune disease, and the prevalence is rising. Autoimmune diseases are a family of more than 80 chronic, often debilitating and, in some cases, life-threatening illnesses.

Moreover, increasing research and development activities and speedy approvals by regulatory authorities for biosimilars, especially in North America, are expected to aid in the remicade biosimilar market growth. For instance, in December 2019, Amgen received the Food and Drug Administration (FDA) approval for AVSOLA (infliximab-axxq) for the treatment of ankylosing spondylitis, psoriatic arthritis, chronic severe plaque psoriasis, ulcerative colitis, Crohn's Disease, and rheumatoid arthritis.

However, complexities in manufacturing and stringent regulatory requirements are expected to hamper the growth of the remicade biosimilar market.

In terms of geography, Europe is expected to witness substantial growth in the remicade biosimilar market due to the high adoption rate due low price of the biosimilars, the presence of top market players, and rapid entry of biosimilars in the region. For instance, in May 2018, Sandoz received European Commission (EC) approval for Zessly (infliximab), a remicade biosimilar for use in Europe.

Competitive Analysis

Major players operating in the remicade biosimilar market are Napp Pharmaceuticals, Nippon Kayaku, Pfizer, Alvogen, Merck and Company, Janssen Biotech, and others.

Key players active in the market are focused on introducing novel remicade biosimilar for multiple indications to strengthen their market position or to strengthen their product portfolio. For instance, in 2017, Merck and Company and Samsung Bioepis jointly introduced Renflexis (infliximab-abda), a remicade biosimilar to treat moderate to severe rheumatoid arthritis, active ulcerative colitis, Crohn’s disease, and other few disease indications.

Location: United States

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex...
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the d...
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood c...
Read more